Buy Enobosarm (MK2866) powder (841205-47-8) hplc≥98% – SARMS Wisepowder
Name Enobosarm (MK2866)
Chemical name ((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide)
Synonyms MK2866; MK 2866; MK-2866; GTX024; GTX 024; GTX-024; Ostarine; Enobosarm.
Molecular Formula C19H14F3N3O3
Molecular Weight 389.334 g/mol
Melting Point 132 to 136 °C (270 to 277 °F)
InChI Key JNGVJMBLXIUVRD-SFHVURJKSA-N
Appearance White to Off-white
Half Life 24 hours
Solubility Soluble in DMSO, not in water
Storage Condition 0 – 4 C for short term (days to weeks), or -20 C for long term (months).
Application Ostarine, aslo known as Enobosarm, and MK-2866 and GTX-024, is selective androgen receptor modulator with anabolic activity.
Testing Document Available
03 Enobosarm(MK2866) General Description
Ostarine, aslo known as Enobosarm, and MK-2866 and GTX-024, is selective androgen receptor modulator with anabolic activity. Selective androgen receptor modulator (SARM) GTx-024 is designed to work like testosterone, thus promoting and/or maintaining libido, fertility, prostate growth, and muscle growth and strength. Mimicking testosterone’s action, this agent may increase lean body mass, thereby ameliorating muscle wasting in the hypermetabolic state of cancer cachexia.
04 Enobosarm (MK2866) History
GTx Incorporated was founded in Memphis in 1997 and licensed rights to enobosarm from the University of Tennessee Research Foundation; the SARM compounds were invented by James T. Dalton, Duane D. Miller, Karen A. Veverka and their research teams at Ohio State University, the University of Tennessee and GTx, respectively.
By 2007, enobosarm was in a Phase II trial, and that year GTx signed an exclusive license agreement for its SARM program with Merck & Co.The companies ended the deal in 2010.
In August 2013, GTx announced that enobosarm had failed in two Phase III clinical trials to treat wasting in people with lung cancer.The company had invested around $35 million in the development of the drug. The company said at that time that is planned to pursue approval of enobosarm in Europe; the company was also still developing GTx-758 for castration-resistant prostate cancer.